相关实验视频
Updated: Feb 26, 2026

13:25
Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
Published on: May 15, 2021
6.7K
通过与布鲁萨托尔联合治疗调节的西斯的药理动力学和毒性
Nan Guo1, Yahui Zhang1, Guiyan Yuan2
1Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Frontiers in pharmacology
|February 25, 2026
概括
布鲁萨托尔改变了西斯的药理动力学,增加了脏度和剂量依赖性毒性. 了解这些影响对于其作为化疗敏感剂的使用至关重要.
科学领域:
- 药理学 药理学是指药理学的学科.
- 毒理学 毒理学 毒理学
- 自然产品 化学 化学
背景情况:
- 来自*Brucea javanica*的四类药物布鲁萨托尔通过增加细胞内药物度来增强西斯普拉丁的疗效.
- 布鲁萨托尔影响西斯的药理动力学和毒性的确切机制尚不完全理解.
研究的目的:
- 在小鼠模型中研究布鲁萨托尔对血药理动力学,组织分布和西斯普拉丁毒性的影响.
- 阐明导致布鲁萨托尔-西斯普拉丁相互作用的潜在机制.
主要方法:
- 在昆明小鼠中使用HPLC-MS进行药理动力学分析,这些小鼠接受单独的西斯普拉丁或与布鲁萨托尔一起服用.
- 毒性评估涉及血清生物标志物 (BUN,肌素),组织分析 (抗氧化剂指数,炎症因素) 和组织病理学.
主要成果:
- 布鲁萨托尔降低了血中西斯的度,增加了其分布体积,并在脏和肺部显著提高了西斯的度.
- 布鲁萨托尔与西斯普拉丁的同时使用导致血清BUN和肌素增加,脏抗氧化能力降低,炎症标志物升高,并观察到管道拥堵.
结论:
- 布鲁萨托尔会改变西斯的药理动力学,导致药物在脏中的积累增加,并加剧剂量依赖性毒性.
- 为了安全有效地使用布鲁萨托尔作为化疗敏感剂,需要对机制和剂量优化的进一步研究.
相关概念视频
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
36
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
36
Drug toxicity: Drug–Drug Interaction
80
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
80
Pharmacokinetics: Drug–Drug Interactions
532
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
532
Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Combined Effects of Drugs: Synergism
7.0K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
7.0K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
771
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
771

